FindTrial
Sign In

Effects of soy isoflavone aglicone on middle-aged women's health-related quality of life

Effects of soy isoflavone aglicone on middle-aged women's health-related quality of life - Effects of soy isoflavone aglicone on middle-aged women's health-related quality of life

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000011876
Enrollment
90
Registered
2013-09-26
Start date
2013-09-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menopausal symptoms

Interventions

8-week treatment with 25 mg of soy isoflavone aglicone 8-week treatment with 12.5 mg of soy isoflavone aglicone 8-week treatment with 0 mg of soy isoflavone aglicone

Sponsors

Tokyo Medical and Dental University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: women with menopausal symptoms

Exclusion criteria

Exclusion criteria: women who are treated with estrogens, Kampo medicine, psychotropic agents etc.

Design outcomes

Primary

MeasureTime frame
health-related quality of life—

Countries

Japan

Contacts

Public ContactMasakazu Terauchi

Tokyo Medical and Dental University Department of Women's Health

teragyne@tmd.ac.jp03-5803-4605

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026